CNBC September 16, 2024
Key Points
– Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some $10 billion on radiopharmaceutical acquisitions and partnerships over the past year.
– Drugmakers are trying to replicate the success Novartis has found with Pluvicto and Lutathera.
– Radiopharmaceuticals are currently available for some neuroendocrine tumors and prostate cancer. They could one day be used for numerous cancers.
Drugmakers are betting that delivering radiation directly to tumors will become the next big cancer breakthrough.
Bristol Myers Squibb, AstraZeneca, Eli Lilly and other pharmaceutical companies have spent some $10 billion on deals to acquire or work with radiopharmaceutical makers. They’ve snapped up smaller upstarts to get their hands on technology that, while in its infancy,...
Today's Sponsors
Today's Sponsor